GAMMA Investing LLC Has $107,000 Stock Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

GAMMA Investing LLC lifted its stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 369.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,799 shares of the company’s stock after acquiring an additional 5,352 shares during the period. GAMMA Investing LLC’s holdings in Dr. Reddy’s Laboratories were worth $107,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of RDY. World Investment Advisors LLC acquired a new stake in Dr. Reddy’s Laboratories during the third quarter worth $3,459,000. Frank Rimerman Advisors LLC acquired a new stake in Dr. Reddy’s Laboratories during the second quarter worth $2,633,000. Natixis Advisors LLC acquired a new stake in Dr. Reddy’s Laboratories during the second quarter worth $777,000. Dimensional Fund Advisors LP boosted its stake in Dr. Reddy’s Laboratories by 12.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company’s stock worth $76,455,000 after buying an additional 114,294 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in Dr. Reddy’s Laboratories during the second quarter worth $557,000. Institutional investors and hedge funds own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Stock Down 2.5 %

Shares of NYSE:RDY opened at $15.41 on Friday. Dr. Reddy’s Laboratories Limited has a 52 week low of $13.43 and a 52 week high of $16.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.36 and a current ratio of 1.92. The company’s fifty day moving average is $14.83 and its 200-day moving average is $15.53. The company has a market capitalization of $12.86 billion, a PE ratio of 24.62 and a beta of 0.51.

Analyst Upgrades and Downgrades

RDY has been the topic of a number of recent research reports. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Barclays reduced their target price on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. Finally, Nomura downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.